ACADIA Pharmaceuticals (ACAD) News Today

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares are near their 52-week high after the company delivered a strong second-quarter earnings report, raised its 2026 revenue outlook, and received a higher price target. However, mixed analyst estimate revisions and a continued “Hold” rating may be limiting further gains.

• Positive Sentiment: Strong Q2 results: ACADIA reported adjusted earnings of $0.18 per share, versus the $0.07 consensus estimate, while revenue of $308 million exceeded expectations of $296.55 million. Revenue increased 16.4% year over year, supported by strong DAYBUE and NUPLAZID sales. ACAD Q2 Earnings and Revenues Beat, 2026 View Raised on Product Sales
• Positive Sentiment: Improved outlook: Management raised or reaffirmed its 2026 revenue outlook at approximately $1.2 billion to $1.3 billion, broadly ahead of the current consensus midpoint. The results reinforce investor confidence in continued product-sales momentum.
• Positive Sentiment: Higher valuation target: Citizens JMP raised its price target from $35 to $36 and maintained a “Market Outperform” rating, implying substantial potential appreciation from recent trading levels. Citizens JMP Price Target Report
• Positive Sentiment: Longer-term earnings estimate increased: HC Wainwright lifted its FY2027 EPS forecast to $1.89 from $1.70, signaling greater confidence in ACADIA’s future profitability.
• Neutral Sentiment: Analyst stance remains cautious: HC Wainwright kept a “Hold” rating despite its estimate changes. The firm raised its Q3 2026 EPS forecast to $0.15 from $0.13 but maintained a Q4 estimate of $0.20.
• Negative Sentiment: Near-term estimate trimmed: HC Wainwright reduced its Q4 2026 EPS forecast slightly, to $0.20 from $0.21. This modest cut may temper enthusiasm following the earnings beat, particularly with the stock trading well above its 50- and 200-day moving averages.